Coordinated action is required to ensure that people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease are treated appropriately with an SGLT-2 inhibitor or GLP-1RA. Here, SLC5A2 is linked to chronic kidney disease.